Imfalda (Rifamycin Sodium)

• Imfalda (rifamycin sodium) is used primarily in the gastrointestinal therapeutic pathway to manage bacterial overgrowth and related complications.
• Intestinal bacterial overgrowth: reduces pathogenic bacteria in the gastrointestinal tract, helping to restore normal flora.
• Prevention of hepatic encephalopathy: decreases ammonia‑producing gut organisms, lowering the risk of encephalopathic episodes.
• Pre‑operative intestinal decontamination: lowers bacterial load before abdominal surgery, reducing postoperative infection risk.

• Rifamycin sodium exerts its antibacterial activity by binding to the β‑subunit of bacterial DNA‑dependent RNA polymerase. This binding blocks the initiation of RNA synthesis, thereby inhibiting transcription of essential genes and leading to bacterial cell death. The drug’s lipophilic nature allows it to penetrate bacterial cell walls, providing activity against a broad spectrum of Gram‑positive and some Gram‑negative organisms, particularly within the intestinal lumen.

Rifamycin sodium may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools or increased frequency.
• Abdominal discomfort: cramps or pain.
• Rash or itching: skin irritation.

Serious or Rare Side Effects

• Severe allergic reaction: anaphylaxis, swelling, difficulty breathing.
• Hepatic dysfunction: jaundice, elevated liver enzymes.
• Hematologic abnormalities: neutropenia, thrombocytopenia, or hemolytic anemia.

When prescribing Imfalda, clinicians should consider several precautionary measures to ensure patient safety.

• Assess renal function: adjust use in patients with severe renal impairment.
• Monitor liver enzymes: watch for signs of hepatic toxicity during therapy.
• Check for hypersensitivity: discontinue if allergic reactions occur.
• Use cautiously in gastrointestinal disease: may exacerbate existing conditions.
• Review concomitant medications: evaluate potential drug interactions.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Rifamycin sodium can interact with other medicines, affecting their efficacy or safety.

Major Interactions (Avoid)

• Co‑administration with macrolide antibiotics (e.g., erythromycin): increased risk of hepatotoxicity.
• Combination with anticoagulants (e.g., warfarin): potentiation of anticoagulant effect, requiring close monitoring.
• Use with other rifamycins (e.g., rifampicin): additive toxicity and overlapping mechanisms.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: rifamycin may reduce hormonal effectiveness, advise alternative contraception.
• Antacids containing aluminum or magnesium: may decrease rifamycin absorption, separate dosing by at least 2 hours.
• Immunosuppressants (e.g., cyclosporine): possible alteration of drug levels, monitor therapeutic concentrations.